Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Raw Materials (2022 - 2026)

Axsome Therapeutics' Raw Materials history spans 5 years, with the latest figure at $11.9 million for Q1 2026.

  • On a quarterly basis, Raw Materials rose 2.81% to $11.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $11.9 million, a 2.81% increase, with the full-year FY2025 number at $10.4 million, up 8.76% from a year prior.
  • Raw Materials hit $11.9 million in Q1 2026 for Axsome Therapeutics, up from $10.4 million in the prior quarter.
  • Over the last five years, Raw Materials for AXSM hit a ceiling of $12.4 million in Q3 2025 and a floor of $2.1 million in Q3 2022.
  • Historically, Raw Materials has averaged $7.4 million across 5 years, with a median of $7.7 million in 2024.
  • Biggest five-year swings in Raw Materials: surged 123.78% in 2023 and later rose 2.81% in 2026.
  • Tracing AXSM's Raw Materials over 5 years: stood at $2.5 million in 2022, then skyrocketed by 123.78% to $5.5 million in 2023, then surged by 72.41% to $9.5 million in 2024, then increased by 8.76% to $10.4 million in 2025, then rose by 14.26% to $11.9 million in 2026.
  • Business Quant data shows Raw Materials for AXSM at $11.9 million in Q1 2026, $10.4 million in Q4 2025, and $12.4 million in Q3 2025.